Pharmacovigilance Trends Shaping Drug Safety Reporting in 2026
We explore the pharmacovigilance trends shaping drug safety in 2026, from AI and real-world data to ICH E2D(R1), to reporting quality for MedSafety Week 2026.
AI Bioweapons Risk Grows as Agent Safeguards Fail
The AI bioweapons risk has entered a new, more worrying phase as Moonshot AI’s Kimi’s jailbreak exposes gaps in agent safeguards.
SynthID Bio: Watermarking AI-Designed Proteins
SynthID Bio embeds hidden watermarks in AI-designed proteins. See how Google DeepMind’s tool could strengthen biosecurity and what pharma R&D should do next.
The UK’s AI Biosecurity Lab Puts Pharma at the Centre of Security
The UK AI Biosecurity Lab brings government, AI developers, and life sciences together to detect biological threats and accelerate medical countermeasures.
FDA Expedited IND Pilot Targets Faster First-In-Human Trials
The FDA’s Expedited IND Pilot introduces rolling review and sponsor-QRI partnerships to accelerate Phase I first-in-human trials while retaining regulatory oversight.
New Targets for Type 2 Diabetes Treatment?
Development of new treatments for people with type 2 diabetes has reached far beyond glucose control. See the new targets, GLP-1 advances, and challenges for development.